Aspirin reducesm ajor atherothrombotice vents across aw ide spectrum of patients with atherosclerotic disease.The occurrence of ischemic events despite of aspirin treatment is afailure of therapy, often denoted 'clinical aspirin resistance'.This is distinguished from laboratorya ssays showing an insufficienti nhibitiono fp lateletf unction, which indicate 'laboratorya spirin resistance'. Laboratory aspirinr esistance has been reported in up to 60% of patients after strokeorperipheralarterial disease, up to 70% in stable coronaryheart disease andevenupto80% in acute myocardial infarction. However, this data must be interpreted carefullybecause of small sample sizes and potential confounding factors sucha sc ompliance,co-morbiditiesa nd large differences between the laboratorym ethodsu sedf or detection.During the pasty ears, evidence has accumulatedthat labKeywords Aspirin resistance,atherosclerosis, plateletfunction, prevalence, clinical outcome oratorya spirin resistance is associated with an increasedi ncidence of major atherothromboticevents,with an up to 13-fold increasedriskofevents in patients withcardiovascular disease. Thus,anindividualizedantiplatelet therapy will have to consider the possibility of aspirin resistance,and the identification of aspirin non-responders mayi mprove antiplatelett herapy in future.Whether an increaseddose of aspirinoranotherantiplateletd rug( e.g. clopidogrel)i nstead or in addition to aspirin should be given is unclear.Prospectivetrials areunderwaywhich addressthis issue.This reviewgives an overviewonthe various clinicalstudiesthat have investigatedthe prevalenceand clinical importance of laboratorya spirin resistance.Moreover, therapeutic options, as well as futureperspectives arediscussed.
Introduction
Since the time of its introduction, aspirinhas become acornerstone in the secondaryprevention of cardiovascularevents. Aspirin inhibits platelett hromboxane (TX)A 2 releaseb ya cetylation of cyclooxygenase( COX)-1 (1) (2) (3) (4) (5) . TXA 2 potentlya ctivatesplatelets. Becauseplatelets lack the synthetic machineryto generate relevant amounts of newC OX-1, aspirin-induced inhibitionlasts for the lifetime of the platelet.
Beyond the molecularm echanism of action, the treatment benefitofaspirin is establishedfor the prevention of cardio-and cerebrovasculare vents, management of acute coronarys yndromesand as an adjuncttopercutaneous and surgical revascularization. The Antithombotic Trialists' Collaboration documentedthat aspirin reducesnon-fatalmyocardialinfarction (MI) by one third,non-fatalstrokebyone quarter,and vascularmortality by one sixthinpatients with vasculardisease (6) .
However, not all individuals equallyr espond to antiplatelet therapya nd thrombembolic eventsm ay occur in presenceo f antiplatelettherapywith aspirin. This hasbeen called"aspirinresistance" or "non-response". Ag enerally accepted definition basedonvalid diagnostic criteriahas notbeen established.
In general, "resistance" means thatadrug is unable to hit its pharmacologicaltarget,eitherdue to the inabilitytoreach it or as aconsequence of an altered target. Accordingly, "aspirinresistance" can be definedasthe inabilityofaspirin to inhibit COX-1-dependent TXA 2 production, and consequentlyTXA 2 -dependent platelet functions (7) . Since laboratoryassays are necessary to identifythis situation, the term"laboratoryr esistance"may be used as well.
On the otherhand,the phenomenon that patients experience atherothrombotic eventsw hile on antiplatelettherapyhas been designated"clinical resistance", even though "treatment failure" seemsmore appropriate. The problem of treatment failureisthat we are unable to determine whether apatient whoexperienced an atherothrombotic event might have undergone amore serious or even lethalevent without aspirin. Moreover,within the in-vivo or in-vitro assays availabletoday, the ranges of "normal"and "re-sistant"are defineddifferently or not defined at all. Altogether, this leads to divergent dataconcerning the prevalenceofaspirin resistanceand divergent readouts of aspirin´sclinical impact.
Aspirinr esistanceh as receivedm uch attention in medical journals and public media. This reviewf ocuseso nc linical aspectsofaspirin resistance. Ashortoverviewisalso givenregarding supposed mechanisms and diagnostic methods. Thep revalenceofaspirin resistanceindifferent patient groups and the impacto nc linical outcome are discussedi nm ore detail. Finally, possible therapeutic approaches and future perspectivesare presented.
Supposed mechanisms of aspirin resistance
The mechanisms of aspirin resistancea re uncertain. Pharmacokinetic and -dynamic mechanisms are likelytoplayarole, including genetic, biologicaland clinicalfactors. The fewknown and manyh ypotheticalmechanisms have beendiscussedindetail by excellent recent reviews (7) (8) (9) (10) . Above all, non-compliancem ay be a" mechanism" of aspirinr esistance. Many studiesonaspirin effectsdid not assess it. Non-compliance in aspirintrials maybeinthe range of 10% (11) ,but is likelyhigher in clinical practice. Thegalenicpreparation mayalso be important: ac omparison of enteric-coateda nd plain aspirin demonstratedthe former to be less effective (12) .
Probably the best establishedm olecular mechanism of laboratoryaspirin resistanceisthe blockade of aspirin´starget,plateletCOX-1, by analgesic,antipyretic and antiphlogistic drugs, such as salicylic acid,i buprofen, naproxen and pyrazoles (13) (14) (15) (16) . This maya lso be true for other organic compounds, such as gallic acid (17) . COX-2-inhibitors (coxibs) and paracetamol are unlikelytointeractwith aspirin.
An increased sympathetic activity attenuatesthe antiplatelet effect of aspirin in healthyvolunteersand patients with previous MI (18, 19) . Followings urgeryo rh aemorrhage, an increased platelet turnoverc an resulti nahigher fraction of platelets capable to formTXA 2 in spiteofaspirin treatment (20) .
Alternative pathwaysfor TXA 2 synthesis and theidentification of prostaglandin-like compounds (isoprostanes) mightalsoexplain ab lunted antiplatelete ffect of aspirin. Fore xample, theC OX-2 isoenzyme may(besidesCOX-1) occur in platelets and, sinceitis lesssensitive to aspirin, contribute to aspirin resistance (21, 22) .
Plateletagonistsotherthan thromboxane mayalso be important. An increased sensitivity to collagen (23) and to ADP (24) have beens uggestedt oc ausea spirin-insensitive plateleta ctivation, sinceboth stimuli areonlypartlyTXA 2 -independent.
Several genevariantshavebeen identified, whichpotentially contribute to heterogeneous responses to aspirin. These include enzymes involved in arachidonic acidm etabolism (including COX-1),plateletglycoprotein and collagenreceptors, as well as proteins involved in blood coagulation (25) .H owever,t he importanceo fg enetic mechanisms for laboratoryr esistanceo r treatment failureisuncertain.
Diagnostic methods
Onlys pecific tests that measure the pharmacologicale ffect of aspirinwill clarify whether platelet hyperreactivity is due to an insufficient pharmacological drug effect or caused by other reasons (7) .Sincethe definition of aspirin resistanceshould be limited to situations where its failuret oh it the target has been documented with appropriate laboratoryt ests, the problemi s thatt he biologicallyi mportant plateleta gonistsi naparticular patient arenot known. Hence,laboratoryassays of aspirinresistanceare surrogatemeasures.Manytests evaluate plateletfunction and do not distinguishaspirin effectsfrom other platelet disorders. Moreover, no standardized definition or laboratorytestis presentlya vailablet oq uantify aspirin resistancei nr elation to normalranges of the diagnostic methods. Nevertheless, numerous tests areavailable. Theseare summarized in Table1together with their advantages and limitations.
As imple method for studyo fn atural haemostasis is the bleeding time,d eterminedb yas tandard skin incision and measurement of the time until bleeding stops. The diagnostic value is very limitedsinceitisnon-specific and poorlystandardized.
Probably the best evaluatedmethodislight transmission aggregometry( LTA), whichm easures the change in light transmission of aplateletsuspension during aggregation in vitro (turbidimetrya ccording to Born).B ecausea spirin blocks platelet TXA 2 synthesis, LTAu sing arachidonca cida sa gonist (about 1m M) is an excellent assayt od etect platelet inhibition by aspirin. LTAinducedbylow collagenconcentrations (≤1µg/ml)is also relatively dependent on TXA 2 .I nc ontrast, ADP-induced LTA does not necessarilyinvolvethe arachidonic acid pathway and is quite insensitive to aspirini nhibition. The effect of epinephrine in LTAisvariable.
Using the same agonists, impedance aggregometrymeasures the change in electrical impedancebetween platinum-electrodes. This method of aggregation allows investigating the antiplatelet effect of aspirininwhole blood,obviating the need to preparea plateletsuspension (26, 27) . Again, arachidonic acid is the optimal and most specific agonist to determine the effect of aspirin.
To reduce the laboratoryr equirements, several "point-ofcare" assays have beendeveloped,such as the plateletfunction analyzer (PFA -100) and the rapidp lateletf unction assay (RPFA).T hese use whole blood and canb ea daptedf or outpatient evaluation sinceanalysis times areshort(minutes).
ThePFA -100simulatesanartificialvesselwith athrombogenic membrane coated with collagenand either epinephrine or ADP.Aconstantn egativep ressure aspirates anticoagulated blood through this vessel(acapillary mimicking the resistance of asmall artery)with high shear force. Aplateletplug forms and gradually occludes the aperture until flowstops.The timetaken to interrupt blood flow(closuretime)isrecorded.The RPFA (UltegraV erifyNowAspirin) is asimple and rapid bedsidetestdetecting the agglutination of fibrinogen-coated beads in response to arachidonic acid by an increase of light transmission.Ifaspirin produced an antiplateleteffect,the beads do not agglutinate and light transmission is unchanged.
The RPFA moderatelyc orrelated with the PFA-100 (epinephrine/collagenc artridge)w ith ac orrelation coefficient of 0.73 (28) , butthe prevalenceofaspirin resistanceinpatients with coronaryd iseases ubstantiallyd iffered between LTA( arachidonic acid) and PFA-100 (29) . Though "point-of-care" assays are attractive for clinical practice, theyare notalwaysprospec- tively validatedinpatients with atherosclerotic diseaseand with respecttothe incidenceofthrombembolicevents in the patients identified as aspirin resistant.
Another laboratoryt estf or diagnosing aspirin resistancei s flow cytometry, whichm easures activation-dependent changes in plateletsurfacemarkers (e.g. P-selectin) after stimulation by variousagonists, including arachidonic acid. This method canbe performed with whole blood (30),but requiressome experience and an expensive equipment.
Since the antiplatelete ffect of aspirin is causedb yt he inhibition of COX-1, TXA 2 is aparticularlysuitableparameter to assess the antiplateleteffect of aspirin. TXA 2 rapidly(withinminutes) hydrolyzes to TXB 2 ,f or whichl aboratoryt estk its (immunoassays) arecommerciallya vailable. It hasbeen suggestedthat aggregometryu sing arachidonic acidt ends to overestimate the incidenceo fa spirin resistance, while TXB 2 is the most specific parametert om easure the pharmacological effect of aspirin (7). Still,T XB 2 measurements require platelets to be stimulated in vitro.T his mayb ed one by addition of plateleta gonists, buti s equallyw ella chievedb yp reparation of seruma t3 7°C.H epatic metabolites of TXB 2 (11-dehydro-TXB 2 )m ay be determinedi n urine as ameasure of TXA 2 formation in vivo,but aproportion of 11-dehydro-TXB 2 probablycomesfrom otherTXA 2 forming cells thanplatelets, whichlimits the specificity for aspirin resistance.
Takentogether,optical and impedanceaggregometryusing arachidonic acida ss timulus,a sw ella st he determination of TXB 2 ,are appropriate methodstodetermine the antiplateleteffect of aspirin. Other agonists also depend on aspirin-insensitive activation pathways, providing limiteda nd less specific information about aspirin'santiplatelet effect. This mayexplain why systematic comparisonsofdifferent laboratorymethods showed onlyaweak or no correlation amongeach other (7).
Prevalenceofaspirinresistance andimpact on clinicaloutcome
Ad iscussiono fa spirin resistancei nc linical practicer equires twoquestions to be addressed: first,how common is laboratory aspirinresistanceand second,does it matter clinically? Table2 givesano verviewabout the studies whichprovided dataonthe clinicali mpact on aspirinr esistanceindefinedp atient groups. An extendedversion of the tablewith additionalstudy information, includingtrials withoutclinical outcome data,isa vailable online at www.thrombosis-online.com.
Taking into account the unsettled use of the term"aspirinresistance" and the diverse diagnostic methods, it is not surpprising thatt he availablep revalenced ataa re inconsistent. For example, the prevalencee stimatesf or laboratorya spirin resistance varies in coronarya rteryd isease( CAD) from 5.2-69, 22.5-83.3 and 20-74% in patients withstableCAD,acutecoronarys yndrome (ACS), and earlya fter coronarya rteryb ypass grafting (CABG), respectively.P atients with cerebrovascular diseasea nd previous strokew ere aspirin-resistant in 5-60%. Moreover, 9-65% of patients with peripheral arterial disease were aspirin resistant.
Hovens et al. found wide differencesinthe prevalenceofaspirin resistanceinameta-analysis of patients taking aspirinfor secondaryp revention and calculatedam ean prevalenceo f 22.4%, 26.0% and 27.3% in patients with CAD,strokeand miscellaneous diseases, respectively (31) . As expected,the analytical method wasanimportant determinant of aspirinresistance. Thep revalencew as loweri ns tudiesu sing arachidonic acidinduced LTA( 15.4%) comparedw ith the PFA-100 method (28.1%), reflecting thatt he PFA-100 probablya lso detects TXA 2 -and aspirin-independent plateletactivation.
Nevertheless, thereisincreasing evidencethat laboratoryaspirin resistanceisclinically important. Several followupstudies have exploredthe relationshipamong aspirintherapy, laboratory datao np lateletr eactivity and the risk of vasculare vents and these have beeni ntegrated in several largem eta-analyses (32, 33) , some specifically addressing the PFA-100 method (34, 35) .
Krasopoulos et al. reviewed20studieswhich related laboratorya spirin resistancet oc ardiovascularo utcome (32).Among 2,930 patients, 810 (28%) were classified as laboratoryaspirin resistant. Overall, cardiovasculare vents occuredin39% of the patients in the aspirin-resistant cohorta nd 16% of the aspirinsensitive patients (odds ratio [OR] 3.85, p<0.001). The OR for increased mortality in laboratorya spirin-resistant patients was even higher (OR 5.99,p<0.003).
Another meta analysis by Snoep et al.p ooled 12 studies, comprising 1,813 patients (33) .The meanprevalenceoflaboratoryaspirin resistancewas 27%. When studieswith cardiovascular outcomeswere pooled,anORof4.4 wascalculated forlaboratoryaspirin resistance. TheORofmyonecrosis after percutaneous coronaryintervention (PCI) was3.1. The pooled OR of major cardiovascularevents in all included studies was3.8. All were statisitcally significant. However, no differencesw ere founda mong three groups of dailya spirin dose (≤100 mg, 101-299 mg and ≥300mg).
Twoa dditional meta analysesf ocussedo nt rials where aspirinn on-responders were identifiedb yt he PFA-100 method. Crescente et al. analysed5 3p ublications reporting aspirin responses (34) .The analysis included64patient populations with at otal of 6,450 subjects. Twenty-onep opulations (2,283 subjects) consisted of apparentlyh ealthys ubjects and 43 populations (4,167 subjects) of patients with cardiovasculardisease. Thep revalenceo fa spirin non-responders identified by the PFA-100 wassignificantly higher in the patients. There wasno obvious relation betweenaspirin dose and aspirinnon-response. While the prevalenceofnon-responders wasnot significantly influenced by the cut-off value of the PFA-100 closuret ime,t he prevalenceofnon-responders wassignificantly higher when the cut-off valueswere establishedbythe investigatorsthemselves, comparedw ith studiesu sing the cut-off levelo ft he PFA-100 manufacturerorfrom literature. Overall,the PFA-100 response to aspirin wasrelated to the risk of vascularevents, with asignificantly higher relative risk of 1.63 in the aspirinnon-responders.
Another meta-analysis by Reny et al.a nalysed sevenn onprospective studies(1,466 patients) and eight prospective studies (1,227 patients) (35) .Inthe non-prospective studies, the prevalenceo fa spirin non-responders rangedf rom 10-22% on the basis of PFA-100 cut-off valuesof130-193 seconds, butafunnel plot identifiedp ublication bias. In the prospective studies, the prevalenceo fa spirin nonresponders ranged from9 .5-49%, on the basis of cut-offv alues of 170-203s econds.T he pooled analysis of the prospectives tudiess howedt hat aspirin non-response wass ignificantly associatedw ith an about two-foldi ncrease of the relative risk for recurrence of ischemic events.
Therefore,both meta-analysesagreed thatPFA -100-defined aspirinnon-responders were morelikelytohavevascular events thanr esponders.B ecauset his assayi sp robably not purely dependent on plateleta ctivation by TXA 2 ,i tr emains unproven whether this results from an absent or insufficient pharmacological effect of aspirinorsimplyreflectsthat patients with more active platelets have an impaired cardiovascularprognosis.
Takentogether,thereisaremarkable heterogeneity of the data, whichbesidesmethodological issuesprobably reflectsthe vast heterogeneity of the manifestations of vasculardisease. Thefollowing discussion, therefore,appraises laboratoryaspirin resistance in relation to the manifestations of cardiovasculardisease.
Coronaryarterydisease (CAD)
Atotal of nine studies investigated the outcome of CAD patients with aspirinresistance (36) (37) (38) (39) (40) (41) (42) (43) (44) . Of these,two trials analysed patients with al ong-term follow-up (years) after MI or ACS, respectively (36, 39) . Additional studies evaluatedthe shortterm outcome in the earlyp eriod of ACS, electiveP CI and elective CABG (45) (46) (47) (48) . Moreover, case-controlstudiesinvestigated the impact of aspirinresistanceonthe occurrence of ACS (49, 50) , on stent thrombosis (51, 52) and on bypass graft thrombosis (53) . In most of the trials, plateletfunction wasassessedbyPFA -100 (7 studies),L TA (4 studies),RPFA(2studies),thromboxane (2 studies),and bleeding time (1 study). Onlytwo studiesinvestigatedaspirin resistancebymore than one method.
In agroupof326 stable CAD patients taking 325 mg/dayaspirin foratleastseven days,Gum et al. noted laboratoryaspirin resistancein17patients (5.2%) (37) . This prospective, blinded studydeterminedaspirin resistancebyLTA.After amean follow up of 1.86years,major events(all-causedeath, MI, or stroke) occurred in fourof17patients in the aspirin-resistant group, compared with 30 of 309 patients in the aspirin-sensitive group. This difference wass tatistically significant (p=0.03). After adjustment for prognosticf actors, as tatistically significant 4.1-fold excesshazard wascalculated (p=0.009), whichwas independent of age, gender and other conventional risk factors. Similar results were reported by Chenetal. in aone-year followu po f4 68 CAD patients receiving 80-325 mg/daya spirin (43) .T he prevalenceo fa spirin resistancew as 27.4%( RPFA assay).Patients identifiedasaspirin-resistant hada3.1-fold increased risk of the composite outcome of cardiovasculardeath, MI, unstableangina requiring hospitalization, strokeortransient ischemic attack (TIA), compared with aspirin-sensitive patients (15.6% vs. 5.3%, p<0.001). After correction for other risk factors, aspirinresistancewas associatedwith ahazard ratio of 2.5.
As mallert rial by Pamukcue ta l. (42)i n2 34 patients with stable CAD taking 100-300 mg/dayaspirin identified 22.2% as aspirin-resistant usingthe PFA-100 (epinephrine).After amean followupof20.6 months,major adverseevents (MI,unstable angina, stroke, cardiacd eath) occurred in 15.4% of the subjects with laboratoryaspirin resistanceand in 11.0% aspirin-sensitive patients, whichw as nots tatistically significant (p=0.269). The study assigned 28 aspirin-resistant patients to additional clopidogrel therapy( 75 mg/day). These experienced less frequently major adverse eventscompared with those not on clopidogrel or whostopped clopidogrel (see also chapter Treatmentofaspirin resistance).
Twoadditional trials studied the role of aspirin resistancein secondaryprevention with previous MI. Cotter et al. (38) identified 52 MI survivors with stableC AD as aspirin responders (100 mg/day), while nine patients were classified as non-compliant or aspirin-resistant, basedonTXB 2 formationinresponse to plateletstimulation by collagen in vitro.Reference valuesof TXB 2 were obtainedf rom patients whose adherence to aspirin wasknown. After one-year followup, cardiacevents (cardiovascular death, MI, unstableangina) were morecommon in the nonadherent/resistant group (1 of 9; 11%),compared with aspirin responders(3of52; 6%).While amultivariate logistic regression analysis identifiedaspirin non-response/resistanceasrisk factor forsevere ischemic events(OR 5.15; p=0.006), thelow patient number wasa ni mportant limitation. Thes econds tudy wasa retrospective substudy of the WA RIS-II trial( 36), whichi ncluded129 survivors of MI receiving 160mg/dayaspirin. This study observed only an on-significant trend for ah igheri ncidenceo fa dverse vasculare vents in aspirin non-responders (PFA-100, epinephrine).
Four studies evaluatedt he outcome after previous ACS, amongw hich twoe valuatede arly ( 41, 44) and twol ong-term outcome (39, 40) .
The clinicaloutcome in 106 ACSpatients without ST-elevation undergoing PCI and stenting wasevaluatedbyCuisset et al. (41) .The patients were divided into quartilesa ccording to the maximalintensity of plateletaggregation (ADP and arachidonic acid-induced LTA). Those in thehighest quartile were definedas "low-responders". Twelve recurrent cardiovascular eventso ccurred within one month despite oral aspirina nd clopidogrel therapy. Lowr esponders showedas ignificant,a lmost six-fold increased risk of cardiovascular eventsduring one month of follow-up. Va llesetal. studiedagroupof62patients with ST-elevation myocardialinfarction (STEMI) whoreceived100-500 mg/ dayaspirin before hospitalization or upon arrivaltothe hospital. Among these,20patients were alreadyonchronic aspirin treatment. Partialinhibition of plateletTXA 2 synthesisafter collagen stimulation in whole blood (<95% inhibition comparedwith aspirin-free healthys ubjects) occuredi n2 1p atients (34%). This group had significantly higher troponin Ta nd CK-MB levels within 48 hours after hospitaladmission (44) .
Stejsdaletal. treated acohortof103 CAD patients with previous ACSwith 100 mg/dayaspirin and measured platelet function by LTA, usingthe relatively nonspecific agonist propyl gallate (39) . Aspirinr esponsivenessw as definedb ya gonist-inducedand spontaneous aggregation. Aspirin resistance occurred in 55% and wasassociatedwith an 88%incidence of recurrent eventsduring the four-yearfollowup. The event ratewas significantly lower(46%) in aspirin responders(p<0.01). More patients were aspirin-resistant at follow-up in the subgroup with recurrent cardiovasculare vents than in those without (72% vs. 8%; p<0.01). In anotherc hronic study,2 0o ut of 105 ACSp atients were aspirin-resistant,a si dentified by the PFA-100 (epinephrine) (40) . During one-year followup, aspirin wasprescribed in doses of 100-300mg/day. Major cardiovascularevents occurred in nine patients (45%)with aspirinresistanceand in 10 patients (11.7%) without( p=0.001). Multivariate analysis identified PFA-100-definedaspirin resistanceasanindependent predictor of major cardiovascularevents.
Twoother studiesdeterminedplatelet responses to aspirin in patients undergoing elective PCI, whoa lsor outinely received clopidogrel. Leve ta l. studied1 50 PCIp atients takinga spirin (80-325mg/day) for at leastone week andobservedaprevalence of laboratoryaspirin resistance of 12.7% (46) . Aspirin resistance wasdefined by at leasttwo of three criteria: RPFA score ≥550, ADP-induced aggregation ≥70% anda rachidonic acid-induced aggregation ≥20%. Within 24 hoursafterintervention, elevation of the CK-MBafterstenting occurred morefrequentlyinthe aspirin-resistantpatients (38.9%vs. 18.3%; p=0.04). Anotherstudy by Chenetal. examinedaspirin responsiveness(RPFA assay) in patients undergoing electiveP CI, receiving 80-325 mg/daya spirin for at leastseven days (45) . Of 151 enrolledPCI patients, 19.2%wereaspirin-resistant and CK-MBwas elevated in 51.7% of them, twice as highasinaspirin responders (24.6%,p=0.006). Thetroponin Ilevels achievedsimilar results.Aspirin resistance (OR2 .9) andb ifurcation lesion (OR2 .8) were the statistically significant, independent predictorsofmyonecrosis in thisstudy.
Patients whou ndergo CABG area th igh risk of thrombotic grafto cclusiona nd laboratorya spirin resistance seemst oo ccur frequentlyinthis setting (30) .The Benefits and RisksofASA on Thrombosis (BRAT) studyr ecruited 289 patients after elective CABG taking 325m ga spirin (47) .Aspirin responses were assessed by bleedingt ime and platelet-derivedT XB 2 in blood samplesa fterc lotting. Aspirin non-responders were definedb y absence of prolongation of bleedingt ime. Surprisingly,p latelet TXB 2 wass imilarlyi nhibitedi na spirin responders and non-responders,and atwo-year followupfailed to showsignificant differencesinMI, unstable angina,cardiacdeath,orstroke,although there wasatrend for more events among nonresponders.The authors concedethatthe aspirin status mayhavebeen misclassified in somepatients by bleedingtimes and that the study wasunderpowered. More recently, Poston et al. evaluated thrombelastography,c ollagen-stimulatedL TA anda rachidonic acid-stimulatedwhole blood flow cytometryamong225 patients, whounderwent electiveoff-pump CABG (48) . Laboratoryaspirin resistance wasobservedonlyin10patients (4%) at baseline. On days 1, 3and 30 after CABG,22(10%), 67 (30%) andseven (2%) patients,respectively, were classified aspirin-resistant. During the 30 dayfollow-up, the incidenceofthromboticbypass graftocclusions was highest in the patients with aspirin resistance,especially in those withendothelial lesions of the graft. Multivariate logistic regressionshowedthataspirin resistance on day1was asignificant, independent predictor of postoperative graftthrombosis (OR2.59).
In addition to the cohortt rials summarized above,s everal case-controls tudiesd emonstrated an impact of aspirinr esistanceonCAD complications,including ACS, stent thrombosis and thrombotic bypass graft occlusion. Among 135 patients admittedfor chest pain and taking aspirin (75-300 mg/day) for at least one week, aspirinresistance(PFA-100)was 9.7% in asubgroup without cardiacd isease, compared with 26.0% (n.s.)i n non-ST-elevation myocardiali nfarction (NSTEMI) and 83.3% (p<0.001) in STEMI (49) .Another study compared104 ACSpatients with 100 patients with stableCAD (54) . Both groups used aspirin for the last sevend ays( dose unknown).A spirin resistance (PFA -100) wass ignificantly (p=0.04) morep revalent in ACSpatients (40.3%) thaninpatients with stableCAD (27%). Acase-controlstudy observedaspirin resistance(LTA) more frequently in patients whodeveloped stentthromboses after coronarystenting (11/23) thaninmatched controls with patent stents (16/50),but this wasnot statisticallysignificant (51) .Asimilar study analyzed 204C AD patients withp reviouss tent implantation amongwhich 102 had intracoronary stentrestenosis (52) . Upont reatment with 100-300m g/daya spirin, 32 patients (31.3%)w ith intracoronarys tent restenosisa nd 11 patients (10.7%)with patent stents were resistant to aspirin, as detected by the PFA-100 method (epinephrine). Finally, ac ase-control study screened 14 CABG patients withatleastone occluded saphenous vein graft after surgery for aspirin resistance (PFA -100, epinephrine) and compared themw ith 14 age-and gendermatchedpatients with well-functioning graftsonlatepostoperative coronaryangiograms(mean follow-up 6.5 years) (53) . Aspirin resistancew as observed in 50% and 7.1% of the patients with and withoutgraft occlusion, respectively (p=0.03). Being aspirinresistant increased the risk of vein graft occlusion 13-fold and multivariate linear regression analysis identifiedt he PFA-100 closure timeasanindependent predictor.
In summary, laboratorya spirin resistancea ppears to be linked to worse long-termoutcomes in patients with all manifestations of CAD,i ncluding those with previous PCIo rC ABG. Different methodstostudy the effect of aspirin, heterogeneous endpoints and the oftenlow numbersofenrolled patients limit the comparability of the studies. The reported event ratios and outcome data are summarizedinTable 2. An extendedversion of this tableisavailableassupplementary material online at www. thrombosis-online.com.
Cerebrovascular disease
The clinicaloutcome of aspirin resistancehas also been studied in patients with cerebrovasculardisease. Grotemeyeretal. determinedaplateletreactivity indexbyanassayfor platelet-platelet and platelet-blood cell adhesion, performed 12 hours after an oraldose of 500 mg/dayaspirin (55) .Of180 strokepatients, 33% were classified aspirin-resistant. All were prescribed 500mgas-pirin threetimesdaily and were followedfor 24 months.Among 174 patients with completetwo-year followup, the aspirin nonrespondershad a9.1-fold increased incidenceofstroke, MI, or vasculardeathincomparison with aspirin responders. Similarly, in acase-controlstudy enrolling 53 patients treated with 100 mg/ daya spirin fors econdaryp revention of TIA or strokeo ver6 0 monthso rl onger,t he rate of aspirin resistance( PFA-100,e pinephrine) wass ignificantly higher in those with recurrent cerebrovascular eventsduring afollowupperiod of >5 years,compared with those without recurrence (34% vs. 0%) (56) .
Hence,much less data areavailableinpatients with cerebrovascular diseasethan in CAD.Nevertheless, laboratoryaspirin resistanceseemsalso associatedwith an impaired clinical outcome in these patients.
Peripheral arterial disease (PAD)
In contrasttoCAD and cerebrovasculardisease, peripheral atherothrombotic eventsa re rarelyl ifethreatening bute xert ah igh impact on quality of life. Ziegleretal. studied52P AD patients receiving 100m g/daya spirin foro ne year after percutaneous transluminalangioplasty.Using the PFA-100 method(epinephrine),fivea spirin non-responders were identified, butt heyd id not significantly differf rom responders in peripheral arterial Doppler indices (57) .Unfortunately, the number of aspirinnonresponderswas very low. Another study included 70 men and 30 womenu ndergoing peripheral angioplasty for intermittent claudication, and complications were evaluatedf or up to 18 months (58).Aspirin wasp rescribed at ad ose of 100 mg/day. Plateletfunction wasassessedusing whole blood aggregometry with arachidonic acid,ADP and collagen as agonists. Depending on thechange of plateletfunction, patients were divided into four classes,and ascorewas calculated thatstratifiedthe resultsinto expected (aspirin responders) and unexpected lowornoantiplatelet effect (aspirin non-responders).During the one-year follow up, plateletr esponsivenesst oa spirin fluctuated considerably. The incidenceo fl aboratorya spirin resistancew as as high as 60%atweeks 4, 8and 52. Eight re-occlusions occurredinthe patients for whom aggregometryhad failedtoprove an antiplatelet effect of aspirin. After an 18-month follow-up period,the risk of arterial reocclusion in the subgroup of aspirin-nonresponsive menw as 87%h igherc ompared with the aspirin responders (p=0.0093). This study is interesting because all patients showed ac ompletelyi nhibited plateletr esponset oa rachidonica cid stimulation. Consequently, activation pathwayso thert han arachidonic acid-stimulated TXA 2 formation seemed to have an important impact on clinical outcome in this aspirin-treated population.
Variousvasculardiseases
In ap ost-hoc study of aspirin-treatedp atients from the Heart OutcomesPrevention Evaluation (HOPE) trial, Eikelboom et al. reported ah igherr isk of vasculare vents in patients with increased urinary 11-dehydro-TXB 2 (59) .The study included data from 976 aspirin-treatedpatients at high risk of cardiovascular disease, with afollowupfor five years.Aspirin responsiveness wass tratifiedi nq uartiles according to urinary 11-dehydro-TXB 2 .The adjusted odds for the composite endpoint MI, stroke, or cardiovasculardeathincreased with the quartileof11-dehydro-TXB 2 levels. Patients in the highestquartile(indicating as-pirin resistance) had a1.8-fold higher risk of the composite endpoint than those in the lowest quartile.T herew as at wo-fold higher risk of MI and a3.5-fold increased risk of cardiovascular deathinthe upper versuslower quartile.This association wasindependent of conventional risk factorsf or vasculard isease. Similarly, Ohmori et al. divided patients withs tablec oronary disease (n=50) or previous stroke(n=86) into quartiles according to collagen-induced aggregation (LTA). Theupper quartilelevel of aggregate formation wasa ssociatedw ith an eight-foldi ncreased risk for cardiovascularevents within a12-month followup (60) .
Overallassessmentofclinical trials
The vast majority of the aforementionedstudiesillustratethat an impairedresponsivenesstoaspirin, as detected by numerous different laboratorym ethods,i sa ssociatedw ith adverses pontaneous (cardiovasculardeath, ACS, stroke, peripheral arterial occlusion)orprocedural (myonecrosis after PCI, reocclusion after angioplasty,graft thrombosis after CABG)clinical eventsindiverse patient populations with an increased risk of atherothrombosis. Thus, patients having laboratoryaspirin resistanceseem to be at ahigherrisk of cardiovascularevents. Unfortunately, the trials examining clinical outcomesh ave oftenbeen retrospective, underpowered and sometimeswithout ap recised efinition of aspirinr esistance. Fews tudiesa ssessed adherence to treatment. Many used composite endpoints, without showing associations with individual outcome parameters. Moreover,m anys tudiesr elyo ne xclusively functional assays, without considering TXA 2 formation, the pharmacological target of aspirin.
Most studies assessed laboratorya spirin resistanceo nlya t one timepoint by one singlei n-vitro test of plateletf unction, usuallywithoutcontrol measurements before aspirin wasgiven. Withoutanestimation of the actual antiplateteleteffect achieved by aspirini na ni ndividual patient, comparedw ith ap re-treatment measurement,i ti sd ifficultt oo btain ar eliabler eadout about the true effect of aspirint herapy. Thus, one maya sk whether these studiesrather demonstrate thatanincreased platelet reactivity wasassociatedwith an increased incidenceofcardiovascular events, whichwould not be too surprising. Certainly, the dilemma is thatw ithholding aspirint reatment for control measurementswould be an ethicalproblem.
Tr eatment of aspirin resistance
Although thee videncef or an association of laboratorya spirin resistancew ith an increased risk of atherothrombotic eventsi s increasing,thereare no establishedguidelines for its diagnosis and treatment. Theoretically, the adjustment of antiplatelettreatment to an individually diagnosedlaboratoryorclinical aspirin resistancemay include an increased aspirin doseorthe addition of (or replacement by)o thera ntiplatelet drugs. Boths trategies will certainlycausemore and/or additional side effects.
Increasingthe doseofaspirin
Several studiesd emonstrated thatl aboratorya spirin resistance can be overcome by ahigherdose, both in patients and in healthy subjects. Using arachidonic acid-inducedp lateleta ggregation, the individual antiplateletdose of aspirin wase valuatedin108 patients with cardiovasculardisease (61) . Adose of 30 mg/day blocked plateleta ggregation near-completely onlyi n4 0%. Fiftypercentrequired adose of 100 mg/dayand the remaining 10% needed 300-500 mg/dayf or complete aggregation inhibition. As imilarh eterogeneity waso bservedb yH elgason et al., whoadministeredincreasing doses of aspirin (325-1300 mg/ day) to 306 patients with previous ischemic strokea nd determinedplateletaggregation (arachidonicacid, collagen, epinephrine, ADP)after twoweeks and at six-month intervals (62). Most patients (74.5%) had complete and 25.5%p artiali nhibition of aggregation at initialtesting. Repeat testing in the patients with partialplateletinhibition revealed that67% achievedcomplete inhibition either by higher aspirin doses or by response fluctuation at the same dose. Overall, 8.2%o fp atients remained aspirin-resistant even at 1,300m g/day. Moreover, plateleti nhibition by afixed aspirind ose wasi nconstant over time.Any modification of aspirintreatment should therefore consider that aspirinresistancecan be transient. Anotherexample for adosedependent effect has beenprovided by Bornstein et al., whocompared 129 patients with asecondstroke, whose aspirin therapy (100-500 mg/day) had clinicallyfailed, withamatched control group with afirst ischemic strokeand subsequent aspirin therapy (63) .Here, the averageperiod between first and recurrent events increased from 10 to 24 monthsw ith aspirind oses increasing from 100 to 500 mg/day. Someotherstudiesprovided inconsistent results probaby due to lowsubjectnumbers (64) (65) (66) . While a recent meta-analysis concluded thatthe prevalenceofaspirin resistanceisassociatedwith aspirindoses ≤100 mg (31),thereis presentlyn ot enough evidencef or the concept that antithrombotic therapeutic effects of aspirin canberestored or improved by an increased dose of aspirin.
Additional or alternative antiplatelet drugs
Clopidogrel Large trials in patientsw ith ACS( CURE [67] ), PCI (CREDO [68] ) or with symptomatic carotid stenosis (CARESS [ 69] ) showedac linical benefit of adding clopidogrel to aspirina s compared with aspirina lone.T wo other multicenter trials (MATCH and CHARISMA) showednoadvantage of dual therapy, despite an increased rate of severe bleeding (70, 71) . Only a subgroup of CHARISMA with prior cardiovasculare vents did benefitfrom dual antiplatelettreatment (72) . Although it is not proven thatthe benefitofdual therapyisrelated to laboratoryaspirin resistance, it is interesting thatthe frequencyofaspirin resistancewas higher in patients whodevelop ACS(where the addition of clopidogrel to aspirinseemsofadvantage) than that in patients with stable coronarydisease (54) .
More recently,P amukcue ta l. prospectively investigated clopidogrel in addition to aspirin in stable CADpatients who were laboratoryr esistantt o1 00-300 mg/day aspirin (PFA -100) (42) .Ofthe 234 enrolled patients, 52 were aspirin resistant. Twenty eight of thelatter were randomizedtoadditionalc lopidogrel (75m g/day) for6 -12 months.P atients receiving aspirin plus clopidogrel experienceds ignificantly fewermajorcardiovascular events compared withthosewithout clopidogrel or whostoppedclopidogrel prematurely. The duration of clopidogrel therapywas asignificantpredictor of major events. This prospectives tudy wasl imited by as mall numberofpatients andmissingdata concerning cessation of aspirin.
It must alsobeconsideredthat asubset of patients do not respond to clopidogrel with the expected inhibition of platelet function (clopidogrel resistance) (73, 74) . There are even patients whodonot respond to either of these treatments: Levetal. identifieda lmost 50% of laboratorya spirin-resistant patients (undergoing elective PCI)asclopidogrel-resistant (46) .
Dipyridamole
Somestudiesassessedthe efficacyofdipyridamole in addition to aspirininpatients at risk of vascularevents. While the metaanalysis of the Antithrombotic Trialists' Collaboration showed no difference betweenthe combination of aspirin-and dipyridamole versusaspirin aloneinhigh-risk patients (6), the ESPS-2 studyreported areduction of vasculare vents (but not vascular death) by adding dipyridamole to av eryl ow dose of aspirin (50 mg/day) (75) .However,ESPS-2was the onlytrial showing a significant reduction of the risk of vasculare vents among 11 trials comparing dipyridamole plus aspirin with aspirin alone (76) .Unfortunately, none of the studies with dipyridamol in addition to aspirin reported laboratoryresults on the antiplateleteffect of these drugs.
Altogether, the availablec linical dataa re insufficient to answerwhetherincreasing the dose of aspirin or the addition of anothera ntiplatelet drug, such as clopidogrel or dipyridamole, has abeneficialimpact on the clinical outcome of patients with laboratoryaspirin resistance.
Implicationsfor clinical practice
On thebasis of the mentioned studies, non-responsiveness or resistancetoaspirin measured in the laboratorymay be associated with increased atherothromboisis. However, there are important shortcomings in the availabled ata, includingd ifferent definitions,s mall sample sizes,u ncertainc ompliance, insufficient dataonpretreatment plateletactivity and methodological problems. Thefollowing shortstatements can be made: 1. Routineevaluation of aspirinresistanceisnot recommended until more data areavailable(Guideline of theInternational Society on Thrombosis and Haemostasis (ISTH) Wo rking Groupo nA spirin Resistance [ 77] ).I ti sp resentlyu nclear whicht reatment is safe and effective in aspirinn on-responders. 2. Most laboratorya nd point-of-care diagnostic tools ares uspect. Single measurements indicate (atb est) the current status of plateletreactivity towards an agonist.Theydonot tell howmuch inhibition has beenachieved by aspirintreatment. 3. If it is decided to assess foraspirin resistanceinanindividual patient, assays using aspirin-sensitive activation pathways, suchasarachidonicacid-induced platelet responses,are preferable. 4. Thromboxanem easurementsi nu rine are contaminatedb y platelet-independent sources, while serumt hromboxane is more platelet-specific. Rapid and easy,inexpensive assays to determine serumthromboxane needtobedeveloped.
5. If aspirinresistanceissuspected or diagnosed, dose and compliance should be examinedfirst. Poor compliancewith aspirinisoften neglected. 6. Aspirinresistancemay be transient. There is little evidence for relevant genetic defects causing aspirin to fail permanently. 7. An establishedcauseofaspirin resistanceisthe adverse interaction with other drugs, such as non-steroidal antiinflammatoryd rugs (NSAIDs),w hich arer egularly consumedb y many patients. Paracetamol and COX-2 selective inhibitors are unlikelytointerfere with aspirin, buthavetheir ownside effects. 8. There is presently not enough evidencethat replacement of aspirin with an agent having adifferent mechanism of action, or its addition to aspirin, improves outcome when laboratory aspirinresistanceispresent. Theseoptions should be based on clinicaljudgement. 9. Higher aspirin doses (e.g. 300 insteadof100 mg/day) mayincrease the laboratoryresponsetoaspirin, butare notproven to be moreclinically active. 10.Slow-releaseformulations of aspirin mayhavealower bioavailability.L aboratorya spirin resistancem ay resolveb y switching to conventional formulations.
Futureresearch
Ak ey question for future researchi st oc omparet he extent to whichthe different assays of plateletfunction (Table 1) and aspirin´s antiplateleta ction independentlyp redict cardiovascular eventsi np atients prescribed antiplateletd oses of aspirin. We needb etters tandardised and validatedl aboratoryo rb edside tests, whichare reallyabletoquantify the antiplateleteffect of aspirinand do not just measure plateletreactivity to anon-specific agonist. This will probablylead to amore stringent definition of aspirin resistance. Va lidatedthreshold levels of functional or biochemical parameters are necessary. Since many potential mechanisms canaccount forthe failureofaspirin to prevent cardiovascular events(seechapter Supposed mechanisms of aspirin resistance), their further characterization is anecessary task, as well as the search forstrategiestopreserve or restore the antiplatelet activity of aspirin. Clinical studies on larger populations using TXA 2 (and therebyaspirin) -specificassays are also required to bettercorrelate laboratoryaspirin resistancewith clinical outcomesthan has beenachieved today(seechapter Prevalenceofaspirin resistancea nd impact on clinical outcome,T able 2).These should also evaluate potentiali mprovementsb ys ystematic alterations in antiplatelettreatment,such as aspirin dose adjustments or addition of or replacement by other antiplateletdrugs, of whichthe current data areverylimited(seechapter Treatmentofaspirin resistance).
Twop rospectiver andomized trials are currentlyu nderway: The ASpirin nonresponsiveness and Clopidogrel Endpoint Trial (ASCET)i sap rospectivec linical trialw herea spirin non-responders amongCAD patients are randomized to continue with aspirin or to switchtoclopidogrel (78) . TheResearch Evaluation to Study Individuals whoShowThromboxane Or P2Y12 Receptor resistance(RESISTOR)evaluatesifpoint-of-care diagnosis of non-responsiveness to orala ntiplatelet agents (aspirin or clopidogrel)and subsequent delivery of eptifibatide canprevent myonecrosis in CAD patients undergoing coronaryi nterventions (79) .
Finally, it remains open if there are definedp atient populations whoh avea ne levatedi ncidence of aspirin resistance. Howa bout gender, racial variation and comorbidities, sucha s diabetes? It is intriguing howm anyq uestions still remain unanswered about this well-studieddrug.
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